Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.19	$3.60	$1.24 ▼ $4.08	$845.81M	0.96	4.16 million shs	3.25 million shs
AVXL Anavex Life Sciences	$9.53 -0.2%	$10.48	$4.93 ▼ $14.44	$818.57M	0.8	1.02 million shs	750,369 shs
IOVA Iovance Biotherapeutics	$2.69 +5.9%	$2.30	$1.64 ▼ $12.51	$973.39M	0.88	17.52 million shs	10.63 million shs
TVRD Tvardi Therapeutics	$28.05 +5.3%	$24.97	$8.13 ▼ $34.31	$263.04M	0.21	22,521 shs	42,712 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	0.00%	-1.85%	-16.93%	+11.54%	+114.09%
AVXL Anavex Life Sciences	0.00%	-4.12%	-25.20%	+26.56%	+50.08%
IOVA Iovance Biotherapeutics	0.00%	+5.49%	-18.24%	+51.12%	-77.26%
TVRD Tvardi Therapeutics	0.00%	+16.88%	+2.78%	-3.58%	+2,804,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.9403 of 5 stars	3.5	2.0	4.0	2.7	0.8	0.6
AVXL Anavex Life Sciences	3.7642 of 5 stars	3.5	1.0	4.7	2.0	0.8	0.6
IOVA Iovance Biotherapeutics	4.6164 of 5 stars	4.2	4.0	4.2	1.5	2.5	0.6
TVRD Tvardi Therapeutics	1.5448 of 5 stars	3.5	0.0	0.0	1.9	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.00	Buy	$6.75	111.60% Upside
AVXL Anavex Life Sciences	3.00	Buy	$44.00	361.70% Upside
IOVA Iovance Biotherapeutics	2.36	Hold	$11.90	342.38% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$64.25	129.06% Upside

Current Analyst Ratings Breakdown

Latest TVRD, IOVA, AKBA, and AVXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
8/19/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/13/2025	AKBA Akebia Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/12/2025	IOVA Iovance Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $14.00
8/8/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
8/4/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
7/23/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/15/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
7/14/2025	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$62.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.28	N/A	N/A	$0.11 per share	29.00
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.06 per share	N/A
IOVA Iovance Biotherapeutics	$164.07M	5.93	N/A	N/A	$1.93 per share	1.39
TVRD Tvardi Therapeutics	$7.14M	36.85	N/A	N/A	$3.51 per share	7.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.17	N/A	N/A	N/A	-17.91%	N/A	-13.47%	11/6/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.57	N/A	N/A	N/A	N/A	-45.67%	-40.21%	N/A
IOVA Iovance Biotherapeutics	-$372.18M	-$1.23	N/A	N/A	N/A	-161.44%	-52.87%	-41.31%	11/6/2025 (Estimated)
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-595.39%	-565.83%	-66.71%	N/A

Latest TVRD, IOVA, AKBA, and AVXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TVRD Tvardi Therapeutics	-$0.51	-$1.00	-$0.49	-$1.00	N/A	N/A
8/12/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	-$0.33	-$0.04	-$0.33	$67.14 million	$59.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.61	1.98	1.84
AVXL Anavex Life Sciences	N/A	8.93	8.93
IOVA Iovance Biotherapeutics	N/A	3.27	2.89
TVRD Tvardi Therapeutics	N/A	4.04	31.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AVXL Anavex Life Sciences	31.55%
IOVA Iovance Biotherapeutics	77.03%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
AVXL Anavex Life Sciences	11.40%
IOVA Iovance Biotherapeutics	10.30%
TVRD Tvardi Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	265.14 million	257.19 million	Optionable
AVXL Anavex Life Sciences	40	85.89 million	76.10 million	Optionable
IOVA Iovance Biotherapeutics	500	361.85 million	324.58 million	Optionable
TVRD Tvardi Therapeutics	80	9.38 million	9.09 million	N/A

TVRD, IOVA, AKBA, and AVXL Headlines

Recent News About These Companies

Tvardi Therapeutics (NASDAQ:TVRD) Trading Down 0.9% - Here's Why

August 24 at 2:48 AM | marketbeat.com

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

August 21 at 11:58 AM | theglobeandmail.com

Tvardi Therapeutics (NASDAQ:TVRD) Releases Quarterly Earnings Results, Misses Estimates By $0.49 EPS

August 16, 2025 | marketbeat.com

Tvardi Therapeutics expects cash to fund operations into Q4 2026

August 15, 2025 | msn.com

Tvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last year

August 15, 2025 | msn.com

Tvardi: Q2 Earnings Snapshot

August 14, 2025 | timesunion.comT

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

August 14, 2025 | finance.yahoo.com

Raymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform Recommendation

July 15, 2025 | msn.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | finance.yahoo.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | businesswire.com

Cantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight Recommendation

July 12, 2025 | msn.com

Tvardi Therapeutics Inc News (TVRD) - Investing.com

June 27, 2025 | investing.com

TVRD Tvardi Therapeutics, Inc.

June 19, 2025 | seekingalpha.com

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating

June 13, 2025 | uk.investing.com

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

June 12, 2025 | benzinga.com

Tvardi Therapeutics Inc (TVRD)

June 7, 2025 | investing.com

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD, IOVA, AKBA, and AVXL Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.19 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.20 +0.02 (+0.47%)

As of 08/22/2025 07:44 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Anavex Life Sciences NASDAQ:AVXL

$9.53 -0.02 (-0.21%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.61 +0.08 (+0.84%)

As of 08/22/2025 07:07 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Iovance Biotherapeutics NASDAQ:IOVA

$2.69 +0.15 (+5.91%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.56 -0.13 (-4.98%)

As of 08/22/2025 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Tvardi Therapeutics NASDAQ:TVRD

$28.05 +1.40 (+5.25%)

As of 08/22/2025 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time